Cargando…

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria

BACKGROUND: Cefiderocol is a promising antimicrobial agent against carbapenem-resistant, Gram-negative bacteria, but susceptibility data from the Chinese mainland are lacking. The aim of the present study was to test the susceptibility of cefiderocol against carbapenem-resistant, Gram-negative bacte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yifan, Li, Yanjun, Zhao, Jin, Guan, Jie, Ni, Wentao, Gao, Zhancheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987888/ https://www.ncbi.nlm.nih.gov/pubmed/35402576 http://dx.doi.org/10.21037/atm-22-889

Ejemplares similares

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
por: Longshaw, Christopher, et al.
Publicado: (2020)

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
por: Wang, Chuanhai, et al.
Publicado: (2022)

Resistance to Cefiderocol Involved Expression of PER-1 β-Lactamase and Downregulation of Iron Transporter System in Carbapenem-Resistant Acinetobacter baumannii
por: He, Yukun, et al.
Publicado: (2022)

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
por: Gavaghan, Victoria, et al.
Publicado: (2022)

Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience
por: Piccica, Matteo, et al.
Publicado: (2023)

In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium
por: Oueslati, Saoussen, et al.
Publicado: (2022)

In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

Performance evaluation of the UMIC(®) Cefiderocol to determine MIC in Gram-negative bacteria
por: Dortet, Laurent, et al.
Publicado: (2023)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
por: Palombo, Marta, et al.
Publicado: (2023)

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
por: Ito, Akinobu, et al.
Publicado: (2017)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020)

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
por: Yamano, Yoshinori
Publicado: (2019)

Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model
por: Matsumoto, Shuhei, et al.
Publicado: (2020)

Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria
por: Lu, Jiayue, et al.
Publicado: (2022)

In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany
por: Ghebremedhin, Beniam, et al.
Publicado: (2021)

In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

The Challenge of Overcoming Antibiotic Resistance in Carbapenem-Resistant Gram-Negative Bacteria: “Attack on Titan”
por: Mancuso, Giuseppe, et al.
Publicado: (2023)

692. In Vitro Antibacterial Activity of Cefiderocol Against a Multi-national Collection of Carbapenem-Nonsusceptible Gram-Negative Bacteria From Respiratory Infections: SIDERO-WT-2014–2017
por: Rao, Sonia N, et al.
Publicado: (2019)

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
por: Nordmann, Patrice, et al.
Publicado: (2019)

Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
por: Jean, Shio-Shin, et al.
Publicado: (2022)

Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics
por: Vaara, Martti
Publicado: (2019)

Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
por: Falcone, Marco
Publicado: (2021)

Correlation between the Antibiotic Resistance Genes and Susceptibility to Antibiotics among the Carbapenem-Resistant Gram-Negative Pathogens
por: Abdelaziz, Salma M., et al.
Publicado: (2021)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

Prevalence of Carbapenem Non-susceptible Gram-Negative Bacteria at Tertiary Care Hospitals in Saudi Arabia
por: Aloraifi, Rayan I, et al.
Publicado: (2023)

648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)

Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria in vitro and in vivo
por: El Hafi, Bassam, et al.
Publicado: (2019)

Antibiotic Susceptibility Testing of the Gram-Negative Bacteria Based on Flow Cytometry
por: Saint-Ruf, Claude, et al.
Publicado: (2016)

Editorial: The global threat of carbapenem-resistant gram-negative bacteria
por: Dropa, Milena, et al.
Publicado: (2022)

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

1544. Efficacy of Human-Simulated Cefiderocol Exposure Against Gram-Negative Bacteria in an Iron-Overloaded Murine Thigh Infection Model
por: Kidd, James M, et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
por: Saisho, Yutaka, et al.
Publicado: (2018)

Comparison of Risk Factors and Outcomes in Carbapenem-Resistant and Carbapenem-Susceptible Gram-Negative Bacteremia
por: Cetin, Sinan, et al.
Publicado: (2021)

Synergistic effect of clinically used antibiotics and peptide antibiotics against Gram-positive and Gram-negative bacteria
por: ZHOU, YULING, et al.
Publicado: (2013)

In Vitro Activity of Cefiderocol against Multi-Drug Resistant Carbapenemase-Producing Gram-Negative Pathogens
por: Boyd, Sandra, et al.
Publicado: (2017)

696. Cefiderocol Susceptibility Against Molecularly Characterized Carbapenemase-Producing Gram-Negative Bacteria in North America and Europe Between 2014 and 2017: SIDERO-WT-2014 to -2016 Studies
por: Sato, Takafumi, et al.
Publicado: (2019)

Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
por: Frontiers Production Office,
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_71h9khbv90v4h2hbrp3e749ilh